**5. Conclusions**

Psychotropic drugs acting on 5-HT receptors, such as AAPDs and 5-HT1A agonists, have been shown to improve social behavior in animals [36; 40; 41]. These results are consistent with the concept that the AVP and 5-HT systems interact both neuroanatomically and neurochemically in the brain areas, e.g. anterior hypothalamus, as demonstrated in Fig. 7 [42]. Therefore, it is reasonable that further research into the neuropeptidergic system, in conjunction with other neurotransmitter/modulator systems, will facilitate the therapeutic strategy for social behavior deficits in patients with schizophrenia and related disorders.

Role for Pituitary Neuropeptides in Social Behavior Disturbances of Schizophrenia 91

, Tadasu Matsuoka and Masayoshi Kurachi *Department of Neuropsychiatry, University of Toyama Graduate School of Medicine and* 

We are grateful for fruitful discussions with Drs. Michio Suzuki, Tsutomu Takahashi and

This work was supported by Health and Labour Sciences Research Grants from Comprehensive Research on Disability, Health and Welfare, Grants-in—Aid for Scientific Research from the Japanese Society for the Promotion of Science, SENSHIN Medical

[1] B.S. McEwen, E. Stellar, Stress and the individual. Mechanisms leading to disease. Arch

[2] E. Frank, R. Landgraf, The vasopressin system--from antidiuresis to psychopathology.

[3] T. Munesue, K. Ashimura, H. Nakatani, M. Kikuchi, S. Yokoyama, M. Oi, H. Higashida, Y. Minabe, Is intranasal administration of oxytocin effective for social impairments in autism spectrum disorder? in: T. Sumiyoshi, (Ed.), Neuroendocrinology and Behavior,

[4] T. Sumiyoshi, Y. Kawasaki, M. Suzuki, Y. Higuchi, M. Kurachi, Neurocognitive assessment and pharmacotherapy towards prevention of schizophrenia: What can we learn from first episode psychosis. Clin Psychopharmacol Neurosci 6 (2008) 57-64. [5] C. Bouza, T. Lopez-Cuadrado, Z. Saz-Parkinson, R. Alcazar, J. Maria, A. Blanco, Natural mortality in schizophrenia: an updated meta-analysis, in: T. Sumiyoshi, (Ed.), Schizophrenia Research: Recent Advances, Nova Science Publishers, New York, 2012,

[6] Y. Kaneda, T. Sumiyoshi, R. Keefe, Y. Ishimoto, S. Numata, T. Ohmori, Brief assessment of cognition in schizophrenia: validation of the Japanese version. Psychiatry Clin

[7] M. Matsui, T. Sumiyoshi, H. Arai, Y. Higuchi, M. Kurachi, Cognitive functioning related to quality of life in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 32

**Author details** 

Tomiki Sumiyoshi\*

Kodai Tanaka.

**6. References** 

pp. (61-80).

(2008) 280-287.

Corresponding Author

 \*

**Acknowledgement** 

*Pharmaceutical Sciences, Toyama, Japan* 

The authors declare no conflict of interest for this work.

Research Foundation, and Takeda Scientific Foundation.

Intern Med 153 (1993) 2093-2101.

InTech, Rijeka, 2012, pp. ( ).

Neurosci 61 (2007) 602-609.

Eur J Pharmacol 583 (2008) 226-242.

**Figure 7.** Photomicrographs of arginine vasopressin (AVP) and serotonin (5-HT), as revealed by double-labelling immunocytochemistry. Shown are AVP and 5-HT fluorescent immunoreactivity acquired through laser scanning confocal microscopy. The same single optical plane is shown for both neurochemical signals in the top black and white photographs. The combination of both digitized images is shown in color on the top right panel. The AVP is depicted in bright yellow and the 5-HT appears as a red/orange. A volume-rendered data set of serial optical sections through the AVP neuron denoted with the star is shown in the bottom color photograph. The green stippling is 5-HT varicosities and putative synapses clustered around the red-colored AVP neuron (denoted by the star). Scale bars: top, 50 μm; bottom, 30 μm. (Ferris C F et al. *J. Neurosci.* 1997;17:4331-43) (Permission obtained from the Society for Neuroscience)
